keyword
MENU ▼
Read by QxMD icon Read
search

Carcinoid syndrome

keyword
https://www.readbyqxmd.com/read/29788534/prospective-evaluation-of-68-ga-dotatate-pet-ct-in-limited-disease-neuroendocrine-tumors-and-or-elevated-serum-neuroendocrine-biomarkers
#1
Sophie Gabriel, Philippe Garrigue, Laetitia Dahan, Frédéric Castinetti, Frédéric Sebag, Karine Baumstark, Cendrine Archange, Jha Abhishek, Karel Pacak, Benjamin Guillet, David Taïeb
CONTEXT: The 68 Ga-labelled somatostatin analogues (68 Ga-DOTA-SSAs) is becoming popular as an important diagnostic tool in neuroendocrine tumors as evidenced by a growing number of reports detailing institutional experience with various DOTA peptides. However, only few prospective studies have compared 68 Ga-DOTA-SSAs and somatostatin receptor scintigraphy (SRS) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and pulmonary neuroendocrine tumors. OBJECTIVE: The aim of our prospective study was to perform head-to-head comparison between 68 Ga-DOTATATE PET/CT and standard imaging work-up (SI) that included multiphasic CT, liver MRI, and SRS using single photon emission computed tomography...
May 22, 2018: Clinical Endocrinology
https://www.readbyqxmd.com/read/29766359/two-types-of-ectopic-cushing-syndrome-or-a-continuum-review
#2
REVIEW
Marta Araujo Castro, Mónica Marazuela Azpiroz
BACKGROUND: Two types of ectopic Cushing syndrome (ECS) are described: ECS associated with aggressive neoplasms, and ECS with indolent and occult tumors, however, there is a lack of studies that thoroughly review their characteristics. METHODS: A systematic review was carried out on PUBMED of all the papers about the ECS, in order to better define the types of this subcategory of Cushing's syndrome, highlighting the differential aspects between these subgroups. RESULTS: It was found that in 50% of cases the prototypic "aggressive" ECS is caused by small cell lung carcinomas (SCLC)...
May 15, 2018: Pituitary
https://www.readbyqxmd.com/read/29754641/the-ectopic-adrenocorticotropic-hormone-syndrome-rarely-easy-always-challenging
#3
REVIEW
Aimee R Hayes, Ashley B Grossman
Despite modern imaging techniques, differentiating ectopic adrenocorticotropic hormone (ACTH) syndrome from pituitary-dependent Cushing's syndrome, Cushing's disease, is especially difficult when well-differentiated carcinoids are the source of ACTH secretion, particularly pulmonary carcinoid tumors. ACTH-secreting pulmonary carcinoids, like the corticotroph adenomas causing Cushing's disease, are often small and difficult to detect, and patients present with a gradual onset of the classical signs and symptoms of Cushing's syndrome, indistinguishable from the presentation of Cushing's disease...
June 2018: Endocrinology and Metabolism Clinics of North America
https://www.readbyqxmd.com/read/29741203/peptide-receptor-radionuclide-therapy-for-advanced-gastroenteropancreatic-neuroendocrine-tumors-from-oncology-perspective
#4
Agnieszka Kolasińska-Ćwikła, Anna Łowczak, Katarzyna Maciejkiewicz Maciejkiewicz, Jarosław Bogdan Ćwikła
Peptide Receptor Radionuclide Therapy (PRRT) is a form of molecular targeted therapy which is performed by using a small peptide (somatostatin analogue - SSA) that is coupled with a radionuclide beta emitting radiation. PRRT is a nuclear medicine for the systemic treatment of non-resectable, metastasized well/moderately differentiated, neuroendocrine tumours (NET) with overexpression of somatostatin receptor. These types of tumours include gastroenteropancreatic neoplasm (GEP-NENs), e.g. arising from the small bowel (often called carcinoid tumours), the pancreas, duodenum or stomach, but also from the large bowel or the lung and many other tissues (so called diffuse neuroendocrine system)...
2018: Nuclear Medicine Review. Central & Eastern Europe
https://www.readbyqxmd.com/read/29724499/changes-in-weight-associated-with-telotristat-ethyl-in-the-treatment-of-carcinoid-syndrome
#5
Martin O Weickert, Gregory Kaltsas, Dieter Hörsch, Pablo Lapuerta, Marianne Pavel, Juan W Valle, Martyn E Caplin, Emily Bergsland, Pamela L Kunz, Lowell B Anthony, Enrique Grande, Kjell Öberg, Staffan Welin, Catherine Lombard-Bohas, John K Ramage, Ashwin Kittur, Qi M Yang, Matthew H Kulke
PURPOSE: In the placebo-controlled Phase III TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) trial, the oral tryptophan hydroxylase inhibitor telotristat ethyl significantly reduced bowel movement (BM) frequency during a 12-week, double-blind treatment period in 135 patients with metastatic neuroendocrine tumors with carcinoid syndrome and ≥4 BMs per day. Patients (mean [SD] age, 63.5 [8.9] years; mean [SD] body mass index, 24.9 [4...
April 30, 2018: Clinical Therapeutics
https://www.readbyqxmd.com/read/29650525/flushing-disorders-associated-with-gastrointestinal-symptoms-part-1-neuroendocrine-tumors-mast-cell-disorders-and-hyperbasophila
#6
REVIEW
Vaibhav Rastogi, Devina Singh, Joseph J Mazza, Dennis Yang, Dipendra Parajuli, Steven H Yale
Flushing is the subjective sensation of warmth accompanied by visible cutaneous erythema occurring throughout the body with a predilection for the face, neck, pinnae, and upper trunk where the skin is thinnest and cutaneous vessels are superficially located and in greatest numbers. Flushing can be present in either a wet or dry form depending upon whether neural-mediated mechanisms are involved. Activation of the sympathetic nervous system results in wet flushing, accompanied by diaphoresis, due to concomitant stimulation of eccrine sweat glands...
April 12, 2018: Clinical Medicine & Research
https://www.readbyqxmd.com/read/29629316/management-of-functional-neuroendocrine-tumors-of-the-pancreas
#7
REVIEW
Kjell Öberg
Pancreatic neuroendocrine tumors (pNETs) constitute a heterogenous group of malignancies with varying clinical presentation, tumor biology and prognosis. The incidence of pNETs has steadily increased during the last decades with an estimated incidence 2012 of 4.8/100,000. Recent whole genome sequencing of pNETs has demonstrated mutations in the DNA repair genes MUTYH and point mutations and gene fusions in four main pathways from chromatin remodeling, DNA damage repair, activation of mechanistic target of rapamycin (mTOR) signaling and the telomere maintenance...
February 2018: Gland Surgery
https://www.readbyqxmd.com/read/29628275/peripheral-serotonin-synthesis-as-a-new-drug-target
#8
REVIEW
Susann Matthes, Michael Bader
The first step in serotonin (5-HT) biosynthesis is catalyzed by tryptophan hydroxylase (TPH). There are two independent sources of the monoamine that have distinct functions: first, the TPH1-expressing enterochromaffin cells (ECs) of the gut; second, TPH2-expressing serotonergic neurons. TPH1-deficient mice revealed that peripheral 5-HT plays important roles in platelet function and in inflammatory and fibrotic diseases of gut, pancreas, lung, and liver. Therefore, TPH inhibitors were developed which cannot pass the blood-brain barrier to specifically block peripheral 5-HT synthesis...
April 5, 2018: Trends in Pharmacological Sciences
https://www.readbyqxmd.com/read/29622373/antidepressants-appear-safe-in-patients-with-carcinoid-tumor-results-of-a-restrospective-review
#9
Elie Isenberg-Grzeda, Meredith MacGregor, Afton Bergel, Stacy Eagle, Fernando Espi-Forcen, Reema Mehta, Konstantina Matsoukas, Jonathan Wills, Diane Reidy-Lagunes, Yesne Alici
INTRODUCTION: Patients living with neuroendocrine tumors have high rates of depression, often necessitating antidepressants, including selective serotonin reuptake inhibitors (SSRI). Neuroendocrine tumors (NETs) secrete vasoactive substances, including serotonin, which contribute to the cluster of symptoms known as carcinoid syndrome (flushing and diarrhea). Controversy exists over whether or not antidepressants are safe in NET. We aimed to study the safety of antidepressant use in NET patients...
March 21, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29607201/clinical-implication-of-men1-mutation-in-surgically-resected-thymic-carcinoid-patients
#10
Xiongfei Li, Mingbiao Li, Tao Shi, Renwang Liu, Dian Ren, Fan Yang, Sen Wei, Gang Chen, Jun Chen, Song Xu
Thymic carcinoid is a rare but very aggressive neuroendocrine tumour derived from the neuroendocrine system. Here we report a male patient with thymic atypical carcinoid. Though thymic carcinoid is relatively common, the gene sequencing profile was performed and the gene sequencing result indicated germline multiple endocrine neoplasia type 1 (MEN1) mutation and two somatic mutations on MEN1 gene and no copy number variation or fusion events were detected. It is well-known that the mutation of MEN1 is the typical manifestation of MEN1 syndrome, which is an autosome dominant disease that includes varying combinations of more than 20 endocrine and non-endocrine tumors...
February 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29602040/prevention-and-management-of-carcinoid-crises-in-patients-with-high-risk-neuroendocrine-tumours-undergoing-peptide-receptor-radionuclide-therapy-prrt-literature-review-and-case-series-from-two-australian-tertiary-medical-institutions
#11
REVIEW
Gonzalo Tapia Rico, Minmin Li, Nick Pavlakis, Gabrielle Cehic, Timothy J Price
Peptide receptor radionuclide therapy (PRRT) is an important therapeutic option for somatostatin receptor (SSTR) positive metastatic and/or inoperable neuroendocrine tumours (NETs). However, in patients with poorly controlled carcinoid syndrome, it may lead to an acute flare of carcinoid symptoms or even carcinoid crisis. We report seven patients who received PRRT with (177 Lu-DOTA0 , Tyr3 ) octreotate (177 Lu-octreotate-LuTate) across two Australian tertiary medical institutions who developed acute flare of carcinoid symptoms/carcinoid crisis during/after PRRT...
March 16, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29587720/spontaneous-adrenocorticotropic-hormone-acth-normalisation-due-to-tumour-regression-induced-by-metyrapone-in-a-patient-with-ectopic-acth-syndrome-case-report-and-literature-review
#12
Hideyuki Iwayama, Sho Hirase, Yuka Nomura, Tatsuo Ito, Hiroyuki Morita, Kazuo Otake, Akihisa Okumura, Junko Takagi
BACKGROUND: Ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS) is caused by tumours releasing ACTH. Ectopic ACTH-producing tumour regression is rarely induced using steroidogenesis inhibitors. We presented a case of EAS in which ACTH production by a lung tumour was reduced by metyrapone (MTP) and also reviewed previous cases of ectopic ACTH production suppressed via steroidogenesis inhibition. CASE PRESENTATION: A 71-year-old female with general fatigue, central obesity and impaired glucose tolerance was diagnosed with Cushing's syndrome due to elevated ACTH (192...
March 27, 2018: BMC Endocrine Disorders
https://www.readbyqxmd.com/read/29547049/lanreotide-therapy-in-carcinoid-syndrome-prospective-analysis-of-patient-reported-symptoms-in-patients-responsive-to-prior-octreotide-therapy-and-patients-na%C3%A3-ve-to-somatostatin-analogue-therapy-in-the-elect-phase-3-study
#13
George A Fisher, Edward M Wolin, Nilani Liyanage, Susan Pitman Lowenthal, Beloo Mirakhur, Rodney F Pommier, Montaser Shaheen, Aaron I Vinik
OBJECTIVE: This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were naïve to prior somatostatin analogue treatment (de novo group). METHODS: Adults with histopathologically confirmed NET and stable CS (diarrhea and/or flushing) were randomized to subcutaneous (SC) lanreotide 120 mg or placebo every 4 weeks for 16 weeks...
March 2018: Endocrine Practice
https://www.readbyqxmd.com/read/29535866/case-series-of-paraneoplastic-cushing-syndrome-in-small-cell-lung-cancer
#14
Carine Ghassan Richa, Khadija Jamal Saad, Georges Habib Halabi, Elie Mekhael Gharios, Fadi Louis Nasr, Marie Tanios Merheb
The objective of this study is to report three cases of paraneoplastic or ectopic Cushing syndrome, which is a rare phenomenon of the adrenocorticotropic hormone (ACTH)-dependent Cushing syndrome. Three cases are reported in respect of clinical presentation, diagnosis and treatment in addition to relevant literature review. The results showed that ectopic ACTH secretion can be associated with different types of neoplasm most common of which are bronchial carcinoid tumors, which are slow-growing, well-differentiated neoplasms with a favorable prognosis and small-cell lung cancer, which are poorly differentiated tumors with a poor outcome...
2018: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/29527003/a-case-of-carcinoid-syndrome-due-to-malignant-metastatic-carcinoid-tumor-with-carcinoid-heart-disease-involving-four-cardiac-valves
#15
Brianna J Shinn, Laura J Tafe, Pantila Vanichakarn
BACKGROUND Carcinoid tumor, benign, low-grade malignant, and high-grade malignant, can be associated with the release of vasoactive substances that cause symptoms including cutaneous flushing, diarrhea, and bronchospasm. In 50-60% of patients with carcinoid syndrome, the vasoactive substances cause fibrosis of the pulmonary and tricuspid heart valves which lead to regurgitation and right-sided heart failure. The right side of the heart is usually affected because monoamine oxidases in the lungs usually inactivate the vasoactive substances...
March 12, 2018: American Journal of Case Reports
https://www.readbyqxmd.com/read/29503551/developments-in-the-treatment-of-carcinoid-syndrome-impact-of-telotristat
#16
REVIEW
David L Chan, Simron Singh
Carcinoid syndrome occurs in 20% of patients with neuroendocrine tumors, and serotonin is usually the main causative hormonal peptide. Carcinoid syndrome, and particularly diarrhea, can significantly impact patients' quality of life. Somatostatin analogs (SSAs) are the mainstay of treatment, but are unable to ameliorate symptoms in all patients due to dose-limiting side effects and tachyphylaxis. Telotristat is a novel oral inhibitor of tryptophan hydroxylase, which is the rate-limiting enzyme in serotonin synthesis...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29496075/yttrium-90-radioembolization-for-unresectable-metastatic-neuroendocrine-liver-tumor-a-systematic-review
#17
REVIEW
Zhongzhi Jia, Weiping Wang
OBJECTIVE: To evaluate the value of yttrium-90 (90 Y) microspheres in the management of unresectable liver metastases secondary to neuroendocrine tumors (NETs). MATERIALS AND METHODS: PubMed, EMBASE, the Cochrane Database of Systematic Reviews, and the "gray" literature (Google Scholar) were searched for all studies related to 90 Y therapy for unresectable liver metastases of NETs. RESULTS: A total of 11 studies and 7 abstracts involving 870 patients were included in the final analysis...
March 2018: European Journal of Radiology
https://www.readbyqxmd.com/read/29485963/carcinoid-heart-disease-early-outcomes-after-surgical-valve-replacement-in-nine-patients
#18
Syed Saleem Mujtaba, Stephen Clark
AIM: To describe the early outcomes of carcinoid patients undergoing surgical heart valve replacement. METHODS: In a retrospective study, records of patients with symptomatic carcinoid heart disease referred for valve surgery between 2012 and 2016 were reviewed. The perioperative and early postoperative outcomes were analyzed. RESULTS: Nine patients, with a mean age of 61 years (range 55-70 years) underwent cardiac surgery for carcinoid syndrome...
February 16, 2018: Heart Surgery Forum
https://www.readbyqxmd.com/read/29457213/trends-in-diagnosis-of-gastroenteropancreatic-neuroendocrine-tumors-gep-nets-in-india-a-report-of-multicenter-data-from-a-web-based-registry
#19
Jagannath Palepu, Shailesh V Shrikhande, Debanshu Bhaduri, Rajiv C Shah, Bhawna Sirohi, Verushka Chhabra, Puneet Dhar, Regulagedda Sastry, Sadiq Sikora
INTRODUCTION: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors. We report data of 407 GEP-NET cases from a neuroendocrine tumor (NET) registry in India. METHODS: The AP-NET registry is an open-label, multicenter, longitudinal observational registry of patients with GEP-NETs in which six tertiary care oncology centers contributed data. Data was prospectively entered in a dedicated computerized database and was reviewed retrospectively. The patients were divided into three cohorts-those diagnosed from 2001 to 2005, from 2006 to 2010, and from 2011 to 2016...
November 2017: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
https://www.readbyqxmd.com/read/29456406/health-related-quality-of-life-anxiety-depression-and-impulsivity-in-patients-with-advanced-gastroenteropancreatic-neuroendocrine-tumours
#20
Alexandra R Lewis, Xin Wang, Laurice Magdalani, Paolo D'Arienzo, Colsom Bashir, Was Mansoor, Richard Hubner, Juan W Valle, Mairéad G McNamara
AIM: To compare health-related quality of life (HRQoL), anxiety, depression, and impulsivity scores in patients with and without carcinoid syndrome (CS), and correlated them with serum 5-hydroxyindoleacetic acid (5-HIAA) levels. METHODS: Patients with advanced gastroenteropancreatic neuroendocrine tumours (GEPNET), with and without CS completed HRQoL QLQ-C30 and QLQ-GI.NET21, Hospital Anxiety and Depression Scale (HADS) and Barratt Impulsivity Scale (BIS) questionnaires...
February 14, 2018: World Journal of Gastroenterology: WJG
keyword
keyword
53037
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"